Table 2.
| Study | Location(s), Year(s) §§ | Total (Interruption) No. of Patients | Interruption Criteria | Follow- Up (Years) | Major Results |
|---|---|---|---|---|---|
| EuroSIDA[69] | Europe, Argentina, Israel 1997–2005 | 3811 (879) | Interruption of ≥3 months | 5.5 | Incidence of AIDS or Death was 1.14 times more likely in patients who experienced interruption (p=0.37) |
| I.Co.N.A.[70] | Italy 1997–2004 | 3142 (721) | Interruption of ≥12 weeks | 0.8 | Patients who experienced interruption had a 2.75 times higher hazard of HIV clinical progression (p=0.03) |
| Swiss HIV Cohort[71] | Switzerland 1996–2008 | 2491 (1271) | Interruption of ≥1 month (2 control groups: Intermittent or constant VL ≥1000) | 8 | Median CD4=427 in interruption group; 525 or 645 in controls; 63% CD4>350 in interruption group; 76% or 87% in controls, (p<0.001) |
| Knobel et al.[72] | Barcelona, Spain 1996–2007 | 540 (231) | Interruption of ≥3 days | 8.3 | Patients who experienced interruption had a 1.39 times higher hazard of treatment failure (CI 1.04–1.85) |
| Wolf et al.[73] | Germany *** | 339 (133) | Interruption of ≥2 weeks | 2 | CD4 no change from baseline in interruption group; significant increase in controls (<0.001) |
| Ncaca et al. (43) | Cape Town, South Africa 2002–2007 | 244 (21) | Interruption of ≥27 days | 4.4 | Odds of failure increase 5.65 times (CI 1.4–22.85) |
††
Table is sorted by descending number of patients within each category. Abbreviations: No.-number, VL- viral load, IRR- incidence rate ratio, CI- 95% confidence interval.
‡‡
Studies included (i) had a control group with no treatment interruption; (ii) had >40 adult participants; (iii) were not limited to patients with multi-drug resistance; and (iv) were completed after 2000.
§§
Year(s) listed are dates of conduction of the study.
***
Dates not available.